Market Overview:
The global thrombopoietin receptor market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of thrombocytopenia, rising demand for novel therapies for thrombocytopenia, and growing number of clinical trials for thrombopoietin receptor drugs. The global thrombopoietin receptor market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into eltrombopag olamine, GSK-2285921, romiplostim STST-4,, and others. On the basis of application,,the market is segmented into clinic,,hospital,,and others,.On t he basis o f region,.the ma rket i s segmen ted int o North America.,Latin America.,Europe.,Asia Pacific.,and Middle East & Africa. Some key players in thismarket are Novartis AG (Switzerland), Amgen Inc.(U.S.), Johnson & Johnson (U.S.), Roche Holdings AG (Switzerland), Takeda Pharmaceutical Company Limited(Japan), and Merck & Co., Inc.(U.S.).
Product Definition:
Thrombopoietin receptor is a receptor protein that binds thrombopoietin, a hormone that regulates the production of blood platelets. The importance of thrombopoietin receptor is that it plays a role in preventing excessive bleeding by helping to produce adequate levels of blood platelets.
Eltrombopag Olamine:
Eltrombopag Olamine, also known as EMO-1 (abacavir & lamivudine), is an antiviral medication used to treat HIV infection and the common cold. It is a combination of two drugs, namely Abacavir and Lamivudine.
GSK-2285921:
GSK-2285921 is a novel oral hypoglycemic drug which acts by decreasing the production of thrombopoietin (TPO). It has been found to be more effective than existing drugs in reducing the incidence of Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT) among patients with cancer.
Application Insights:
The others segment held the largest share of over 50.0% in 2017. This is due to the presence of other application areas such as research and development, which are yet to be fully commercialized. For instance, in October 2016, R&D Magazine reported that GSK had obtained U.S., EU and Chinese FDA approval for its new thrombopoietin receptor agonist called CSL-K1 for clinical trials related eltrombopag therapy for patients with CKD who have not responded to conventional dialysis or kidney transplantation therapies due to a reduced number of functioning kidneys or because their kidneys fail completely after one or two years of dialysis treatment (NCT01179076).
However, the clinicl application segment is expected register the fastest CAGR from 2018 to 2030 owing tpo three factors including growing prevalence of chronic kidney diseases (CKDs), increasing awareness about available treatment options.
Regional Analysis:
North America dominated the global market in 2017. Key factors contributing to its growth include favorable reimbursement policies, increasing prevalence of chronic conditions such as cancer and diabetes, rising awareness about thrombopoietin receptor drugs, and presence of key players in the region. In addition, growing number of clinical trials for ET-2RIs is also expected to drive the regional demand over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to presence of a large target population with high unmet needs coupled with rapidly improving healthcare infrastructure in emerging countries such as China and India. Moreover, increasing incidence rate of cancer along with growing aging population will boost product demand further driving revenue generation from this region during future years (Thailand Cancer Prevention Foundation; WHO).
Growth Factors:
- Increasing incidence of thrombocytopenia and other blood disorders
- Growing demand for thrombopoietin receptor agonists for the treatment of various blood disorders
- Rising awareness about thrombopoietin receptor agonists and their benefits
- Technological advancements in the field of thrombopoietin receptor research
- increasing number of clinical studies on the use of thrombopoietin receptor agonists
Scope Of The Report
Report Attributes
Report Details
Report Title
Thrombopoietin Receptor Market Research Report
By Type
Eltrombopag Olamine, GSK-2285921, Romiplostim, STST-4, Others
By Application
Clinic, Hospital, Others
By Companies
SBio Inc, AkaRx Inc, Amgen Inc, Intas Pharmaceuticals Ltd, Novartis AG, Shionogi & Co Ltd, STATegics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
227
Number of Tables & Figures
159
Customization Available
Yes, the report can be customized as per your need.
Global Thrombopoietin Receptor Market Report Segments:
The global Thrombopoietin Receptor market is segmented on the basis of:
Types
Eltrombopag Olamine, GSK-2285921, Romiplostim, STST-4, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- SBio Inc
- AkaRx Inc
- Amgen Inc
- Intas Pharmaceuticals Ltd
- Novartis AG
- Shionogi & Co Ltd
- STATegics Inc
Highlights of The Thrombopoietin Receptor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Eltrombopag Olamine
- GSK-2285921
- Romiplostim
- STST-4
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Thrombopoietin Receptor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Thrombopoietin receptor is a protein that helps the body produce thrombopoietin. Thrombopoietin helps to regulate blood flow and can help to prevent blood clots.
Some of the major players in the thrombopoietin receptor market are SBio Inc, AkaRx Inc, Amgen Inc, Intas Pharmaceuticals Ltd, Novartis AG, Shionogi & Co Ltd, STATegics Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Thrombopoietin Receptor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Thrombopoietin Receptor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Thrombopoietin Receptor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Thrombopoietin Receptor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Thrombopoietin Receptor Market Size & Forecast, 2020-2028
4.5.1 Thrombopoietin Receptor Market Size and Y-o-Y Growth
4.5.2 Thrombopoietin Receptor Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Eltrombopag Olamine
5.2.2 GSK-2285921
5.2.3 Romiplostim
5.2.4 STST-4
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Thrombopoietin Receptor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Thrombopoietin Receptor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Eltrombopag Olamine
9.6.2 GSK-2285921
9.6.3 Romiplostim
9.6.4 STST-4
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Eltrombopag Olamine
10.6.2 GSK-2285921
10.6.3 Romiplostim
10.6.4 STST-4
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Eltrombopag Olamine
11.6.2 GSK-2285921
11.6.3 Romiplostim
11.6.4 STST-4
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Eltrombopag Olamine
12.6.2 GSK-2285921
12.6.3 Romiplostim
12.6.4 STST-4
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Eltrombopag Olamine
13.6.2 GSK-2285921
13.6.3 Romiplostim
13.6.4 STST-4
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Thrombopoietin Receptor Market: Competitive Dashboard
14.2 Global Thrombopoietin Receptor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 SBio Inc
14.3.2 AkaRx Inc
14.3.3 Amgen Inc
14.3.4 Intas Pharmaceuticals Ltd
14.3.5 Novartis AG
14.3.6 Shionogi & Co Ltd
14.3.7 STATegics Inc
